期刊
ATHEROSCLEROSIS
卷 222, 期 1, 页码 50-58出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2012.01.046
关键词
Coptisine; Myocardial infarction; Rho kinase; Isoproterenol; Anti-oxidative; Mitochondrial respiratory function
资金
- Special Foundation on Scientific and Technological Basic Work [2007FY130100]
- National Scientific & Technological Major Special Project significant creation of new drugs [2009ZX09302-003, 2009ZX09501-021]
Objective: Because myocardial infarction is a major cause of morbidity and mortality worldwide, protecting the heart from the ischemia is the focus of intense research. Coptisine is an isoquinoline alkaloid extracted form Coptidis Rhizoma. This study aims to elucidate if coptisine is responsible for cardioprotection using myocardial infarction (MI) rat models and investigate its potential mechanism of action. Methods: Myocardial infarction was produced in rats with 85 mg kg(-1) isoproterenol administered subcutaneously twice at an interval of 24 h. The rats were randomized into 7 groups: (I) Normal; (II) ISO; (III) ISO + fasudil; (IV) ISO + isosorbide dinitrate (ISDN) and (V-VII) ISO + coptisine (25, 50 and 100 mg kg(-1)). Cardiac function and markers of cardiac ischemic were assessed after MI. Results: Rats pretreated with coptisine (25, 50 and 100 mg kg(-1)) for 21 days and received subcutaneously injected with ISO (85 mg kg(-1)) on the 20th and 21st day at an interval of 24 h. The results suggested that coptisine has strong antioxidant activity, and it can maintain cell membrane integrity, ameliorate mitochondrial respiratory dysfunction, reduce myocardial cells apoptosis, inhibit RhoA/ROCK expression induced by high-dose isoproterenol administration. Conclusions: Coptisine provided cardioprotection in a model of myocardial infarction, and therefore should be considered as a novel adjunctive therapy for attenuating myocardial damage. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据